- Home
- CHRS vs NKSH Comparison
CHRS vs NKSH Comparison
Compare CHRS & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | NKSH |
|---|---|---|
| Founded | 2010 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.5M | 243.3M |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CHRS | NKSH |
|---|---|---|
| Price | $1.60 | $35.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 14.0K |
| Earning Date | 03-09-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.14% |
| EPS Growth | ★ 472.00 | N/A |
| EPS | 1.43 | ★ 1.56 |
| Revenue | N/A | ★ $7,474,000.00 |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | ★ $1.13 | $23.46 |
| Revenue Growth | N/A | ★ 5.68 |
| 52 Week Low | $0.72 | $23.75 |
| 52 Week High | $2.62 | $40.00 |
Technical Indicators
Market Signals| Indicator | CHRS | NKSH |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 39.07 |
| Support Level | $1.55 | $35.42 |
| Resistance Level | $1.75 | $37.65 |
| Average True Range (ATR) | 0.11 | 0.92 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 10.85 | 24.53 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.